# Andrew Schwab

> Andrew Schwab is a Series A investor at 5AM Ventures backing Biotechnology and Health Care. See 18 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [5AM Ventures](https://shizune.co/investors/profile/5am-ventures)
- Location: San Francisco, United States
- Total investments: 18
- Last investment: Sep 2025
- Lead investor: 28%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/anschwab/
- X (Twitter): http://twitter.com/Schwab5AM

Andrew Schwab is a Series A investor at 5AM Ventures in San Francisco focused on Biotechnology and Health Care. Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures.Prior to founding 5AM Ventures in 2002, Mr. Schwab was a Principal at Bay City Capital (BCC). After joining BCC in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx.Prior to joining BCC, Mr.Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities.At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Anaphore, Cleave Biosciences, DVS Sciences, Flexion Therapeutics, Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix) and Viveve.Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of the 1992 Final Four soccer team. Mr. Schwab is based in the Menlo Park, CA office.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 44% |
| Health Care | 6 | 33% |
| Therapeutics | 5 | 28% |
| Biopharma | 3 | 17% |
| Medical Device | 2 | 11% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 44% |
| Series B | 5 | 28% |
| Post-IPO Equity | 2 | 11% |
| Seed | 1 | 6% |
| Series C | 1 | 6% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CAMP4 Therapeutics | CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients. | $50M | Post-IPO Equity | Sep 10, 2025 |  |
| Fellow Health | Fellow Health provides peer-reviewed, clinical semen analysis solutions that patients can conveniently perform at home. Their services cover full semen analysis, post-vasectomy semen analysis, and cryopreservation. | $24M | Series B | Jul 15, 2025 |  |
| Escient Pharmaceuticals | Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $120M | Series C | Nov 28, 2022 |  |
| Novome Biotechnologies | Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. | $43.5M | Series B | Sep 13, 2022 |  |
| Fellow Health | Fellow Health provides peer-reviewed, clinical semen analysis solutions that patients can conveniently perform at home. Their services cover full semen analysis, post-vasectomy semen analysis, and cryopreservation. | $24M | Series A | Aug 01, 2022 |  |
| CAMP4 Therapeutics | CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients. | $100M | Series B | Jul 20, 2022 |  |
| CAMP4 Therapeutics | CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients. | $45M | Series A | Jun 15, 2021 |  |
| Escient Pharmaceuticals | Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $77.5M | Series B | Sep 14, 2020 |  |
| Novome Biotechnologies | Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. | $33M | Series A | Jan 07, 2020 |  |
| Escient Pharmaceuticals | Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $40M | Series A | May 09, 2018 |  |

10 of 18 investments shown.

## Co-investors
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 6 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 2 deals together
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 2 deals together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 2 deals together

## About 5AM Ventures

VC Fund · Menlo Park, United States

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

5 contacts available at 5AM Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Kush Parmar | Managing Partner | https://shizune.co/investors/profile/kush-parmar |
| Scott Rocklage | Founding Partner | https://shizune.co/investors/profile/scott-m-rocklage |
| Andrew Schwab | Managing Partner | https://shizune.co/investors/profile/andrew-schwab |
| Deborah Palestrant | Partner | https://shizune.co/investors/profile/deborah-palestrant |
| James W. Young | Venture Partner | https://shizune.co/investors/profile/james-w-young |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Andrew Schwab invest in?

Andrew Schwab invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andrew Schwab last invest?

The most recent investment recorded for Andrew Schwab closed in Sep 2025. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co